Buenos Aires, Argentina — On December 16, 2025, the AnchorMan^® Left Atrial Appendage Closure System (hereinafter referred to as "AnchorMan^®"), independently developed by Shanghai MicroPort CardioAdvent Co., Ltd, a wholly-owned subsidiary of MicroPort CardioFlow Medtech Corporation (02160.HK), successfully completed its first commercial clinical application in Latin America at the Instituto Cardiovascular de Buenos Aires (ICBA), a leading specialized cardiovascular hospital in Argentina.

The procedure was performed by a team led by the renowned expert, Professor LUIS IGNACIO MONDRAGÓN, at ICBA. Postoperative evaluation confirmed optimal device positioning with no residual leak or clinical complications, marking a complete success for the surgery.

Case Details

Preoperative CT Assessment:

The patient's left atrial appendage (LAA) exhibited a reverse chicken-wing morphology. The ostium was elliptical with a narrowed neck. The LAA ostium measured 11 mm, the pouch diameter was 14 mm, and the main lobe depth was 14 mm. A low and anterior interatrial septal puncture site was selected.

Intraoperative Procedure and Surgical Outcome:

LAA angiography was performed in RAO 30° CAU 20°, confirming a reverse chicken-wing anatomical structure. The widest part of the ostial pouch measured 13 mm with a depth of 14 mm. A 20 mm AnchorMan^® closure device was selected.

Device Deployment Process:

A combination of the "unsheathing method" and "push-pull technique" was employed. The delivery sheath was first advanced counterclockwise into the distal LAA. The closure device was then partially deployed using the unsheathing method, taking on a "bud-like" shape. Subsequently, using the push-pull technique, the device was slowly advanced distally. Leveraging the rounded, high-safety distal tip design of the AnchorMan^® LAAC system, the full depth of the appendage was utilized to achieve complete closure.

Surgical Outcome:

After deployment, the closure device conformed well to the LAA anatomy. A tug test confirmed stable device position without displacement. The compression ratio was ideal, and excellent immediate sealing was achieved.

Expert Evaluation:

Following the procedure, Professor LUIS IGNACIO MONDRAGÓN commented:

"The semi-closed structure combined with the rounded distal design of AnchorMan^® significantly enhances the smoothness and controllability of intraoperative manipulation. The device offers flexible movement and easy adjustment, which helps us better tackle the challenges posed by various complex LAA anatomies. It also contributes to reducing procedural difficulty and risk to some extent."

Summary:

Recently, while continuing to deepen its presence in the mainland China market, AnchorMan^® has successively expanded into the Hong Kong & Macau, European, and Latin American markets, achieving successful post-market clinical implants in Poland, Germany, and Argentina. This series of milestones signifies the product's steady entry into the global market for stroke prevention in atrial fibrillation and its growing recognition in the international arena.

Looking ahead, the company will accelerate the global commercial deployment of AnchorMan^® and fully leverage the resource integration and synergistic advantages brought by the strategic merger with MicroPort CRM. This will enable a concerted effort to build a globally leading integrated diagnosis and therapy platform spanning Structural Heart, Rhythm Management, and Heart Failure Management. Committed to building a leading enterprise of emerging technologies in cardiac diagnosis and therapy, the company aims to deliver innovative solutions to a broader global patient population.